HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leitha, T. Articles by Dudczak, R. Search for Related Content PubMed PubMed Citation Articles by Leitha, T. Articles by Dudczak, R.

The Role of Iodine-123-Tyr-3-Octreotide Scintigraphy in the Staging of Small-Cell Lung Cancer

University Clinics of Nuclear Medicine and Internal Medicine, Vienna
Chemical Institute, Austrian Research Center, Seibersdorf
Center for Pulmonary Diseases, Vienna
Second University Clinic of Surgery, Vienna, Austria

Correspondence: For correspondence and reprints contact: Thomas Leitha, MD, University Clinic of Nuclear Medicine, University Vienna, Waehringer Guertel 18-20; 1090 Vienna, Austria

ABSTRACT

The purpose of this study is to investigate the role of ¹²³I-Tyr-3-octreotide scintigraphy in staging small-cell lung cancer (SCLC), its efficacy for the discrimination of limited and extensive disease stages and its regional sensitivity for different metastatic locations. Twenty patients with histologically confirmed SCLC and 50 radiologically staged tumor sites were investigated by an imaging protocol including dynamic (0–30 min p.i.), static (30 min, 90 min, 4 hr, 24 hr p.i.) and SPECT (90 min p.i.) studies. The primary tumor site was visualized in 84%, whereas the best delineation was noted in early planar (15–30 min p.i.) and SPECT studies, due to a rapidly decreasing tumor-to-background ratio. Lymph node metastases were seen in 73%, but SPECT was needed anatomical localization. All three adrenal metastases could be identified in sequential planar images. One clinically unsuspected brain metastasis was seen, whereas a second clinically overt metastasis was not visualized. The global and regional sensitivity for liver and bone metastases was unsatisfactory. In summary, 78% (7/9) of the patients with extensive disease were correctly identified by scintigraphy alone. We conclude that ¹²³I-Tyr-3-octreotide scintigraphy is a substantial tool in the staging work-up of SCLC if it is performed initially to allow fast identification of patients with extensive disease stages and save additional radiological or invasive examinations. Yet, ¹²³I-Tyr-3-octreotide scintigraphy cannot substitute liver sonography or conventional bone scanning in patients who have no scintigraphic evidence of distant tumor spread.

This article has been cited by other articles:

				J. P. Norenberg, B. J. Krenning, I. R.H.M. Konings, D. F. Kusewitt, T. K. Nayak, T. L. Anderson, M. de Jong, K. Garmestani, M. W. Brechbiel, and L. K. Kvols 213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model Clin. Cancer Res., February 1, 2006; 12(3): 897 - 903. [Abstract] [Full Text] [PDF]